Research programme: fixed combinations for cardiovascular indications - HanAll Biopharma

Drug Profile

Research programme: fixed combinations for cardiovascular indications - HanAll Biopharma

Alternative Names: HL013 (hypertension/hyperlipidemia functional combination) - HanAll Biopharma; HL037; HL053; HL162

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HanAll Biopharma
  • Class
  • Mechanism of Action Angiotensin type 2 receptor antagonists; Calcium channel antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Hyperlipidaemia; Hypertension

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hyperlipidaemia in South Korea (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hypertension in South Korea (PO)
  • 08 Feb 2011 This programme is ongoing in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top